2018
PoNS Therapy™ receives authorization in Canada for the treatment of balance deficit due to mmTBI

2019
PoNS™ becomes available commercially, for the first time, to patients in Canada for the treatment of balance deficit due to mmTBI

2020
Helius Medical receives FDA Breakthrough Designation for PoNS treatment of gait deficit due to symptoms of MS

Helius Medical submitted request for FDA de novo classification

2020
PoNS Therapy receives authorization in Canada for the treatment of gait deficit due to mild and moderate symptoms of MS

2021
Helius Medical receives US marketing authorization for the PoNS® device

2021
Helius Medical receives FDA breakthrough designation for PoNS treatment of gait deficit due to stroke

2021
Helius Medical receives PoNS® market authorization in Australia

2022
PoNS® becomes available commercially by prescription, for the first time, to patients in the U.S. for the treatment of gait deficit due to MS

2022
Helius Medical launches online PoNS Therapy training for rehabilitation specialists

Helius Medical Technologies, Inc. news

Contact supplier